The successful tumor delivery of mesothelin-targeted imaging agents utilizing full monoclonal antibodies has been reported in patients with mesothelioma, ovarian cancer and PDAC, providing proof that MSLN-targeting can result in tumor-specific delivery [110,111]. This evidence concerns the gene MSLN and ovarian carcinoma.